BOSTON – In 2012, the last time the BIO International Convention was held in Boston, Jim Greenwood, president and CEO of BIO, noted in a statement that "the overarching sentiment shared by the majority of attendees is a positive outlook for the future of our industry." His view was spot on because in the intervening five years the industry has been on a tear, with the Nasdaq Biotechnology Index recording a 155 percent jump in value. Fundraising has also been off the charts and business development has continued at a frenetic pace.